---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007473"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:29:02.034859+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PAVMED's Lucid Diagnostics raises $13.625M via Series A Preferred private placement

## Summary
- Issued 13,625 shares of Series A Convertible Preferred at $1,000/share; gross proceeds $13.625M.
- Closing occurred on March 7, 2023; private placement with accredited investors.
- Certificate of Designation filed with Delaware establishing Series A Preferred terms.
- Further details incorporated by reference to Lucid Diagnostics' Form 8-K filed March 13, 2023.

## SEC filing metadata
- accession: 0001493152-23-007473
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315223007473/0001493152-23-007473-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315223007473/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007473
- JSON: https://secwatch.observer/filing/0001493152-23-007473.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007473.txt

## Key facts
- Material Agreements
  PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at $13.625 million (effective 2023-03-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $13.625 million
  - Effective: 2023-03-07
  source text: On March 7, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ” or the “ Company ”) entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors for the sale of 13,625 shares of newly designated Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), at a purchase price of $1,000 per share, for aggregate gross proceeds to the Company of $13.625 million, in a private placement (the “ Preferred Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315223007473/0001493152-23-007473-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.